Login to Your Account



Tau-Targeting Approach Put to Test in TauRx's Phase III

By Nuala Moran
Staff Writer

Wednesday, October 31, 2012

LONDON – TauRx Therapeutics Ltd. said it has recruited the first patients to two Phase III Alzheimer's disease trials in which it aims to provide the first definitive proof that breaking down tangles of tau protein in the brain has a disease-modifying effect in the mild to moderate stages of pathology.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription